David Mathes
Concepts (404)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammaplasty | 42 | 2025 | 136 | 10.300 |
Why?
| | Perforator Flap | 14 | 2025 | 35 | 5.250 |
Why?
| | Surgery, Plastic | 11 | 2025 | 56 | 3.240 |
Why?
| | Vascularized Composite Allotransplantation | 5 | 2024 | 31 | 3.110 |
Why?
| | Surgical Flaps | 12 | 2024 | 146 | 3.010 |
Why?
| | Transplantation Tolerance | 9 | 2024 | 37 | 2.570 |
Why?
| | Graft Survival | 16 | 2024 | 520 | 2.330 |
Why?
| | Graft Rejection | 14 | 2024 | 551 | 2.190 |
Why?
| | Epigastric Arteries | 15 | 2025 | 30 | 2.100 |
Why?
| | Free Tissue Flaps | 7 | 2025 | 59 | 2.040 |
Why?
| | Rectus Abdominis | 5 | 2024 | 17 | 1.830 |
Why?
| | Skin Transplantation | 9 | 2018 | 85 | 1.680 |
Why?
| | Microsurgery | 10 | 2024 | 78 | 1.590 |
Why?
| | Breast Neoplasms | 19 | 2025 | 2340 | 1.570 |
Why?
| | Postoperative Complications | 23 | 2025 | 2938 | 1.510 |
Why?
| | Myocutaneous Flap | 3 | 2024 | 10 | 1.500 |
Why?
| | Composite Tissue Allografts | 4 | 2016 | 8 | 1.480 |
Why?
| | Facial Transplantation | 5 | 2014 | 10 | 1.470 |
Why?
| | Breast Implants | 6 | 2025 | 27 | 1.420 |
Why?
| | Breast Implantation | 5 | 2025 | 19 | 1.320 |
Why?
| | Hand Transplantation | 5 | 2011 | 9 | 1.320 |
Why?
| | Surgical Wound Dehiscence | 4 | 2024 | 22 | 1.130 |
Why?
| | Immune Tolerance | 8 | 2024 | 381 | 1.100 |
Why?
| | Transplantation Chimera | 6 | 2014 | 57 | 1.070 |
Why?
| | Bone Marrow Transplantation | 6 | 2014 | 294 | 1.040 |
Why?
| | Acellular Dermis | 3 | 2022 | 11 | 0.980 |
Why?
| | Transplantation, Homologous | 14 | 2016 | 417 | 0.970 |
Why?
| | Fat Necrosis | 2 | 2022 | 12 | 0.890 |
Why?
| | Angiography | 5 | 2022 | 207 | 0.870 |
Why?
| | Craniosynostoses | 4 | 2026 | 70 | 0.850 |
Why?
| | Iliac Artery | 1 | 2024 | 57 | 0.840 |
Why?
| | Abdominal Wall | 3 | 2025 | 27 | 0.830 |
Why?
| | Breast | 5 | 2024 | 158 | 0.820 |
Why?
| | Immunosuppressive Agents | 8 | 2024 | 860 | 0.820 |
Why?
| | Retrospective Studies | 41 | 2025 | 16942 | 0.810 |
Why?
| | Body Dysmorphic Disorders | 1 | 2023 | 11 | 0.810 |
Why?
| | Rhinoplasty | 1 | 2023 | 33 | 0.780 |
Why?
| | Mastectomy | 8 | 2025 | 164 | 0.780 |
Why?
| | Immunotoxins | 4 | 2025 | 55 | 0.770 |
Why?
| | Surgical Wound Infection | 8 | 2025 | 329 | 0.760 |
Why?
| | Preoperative Care | 5 | 2012 | 383 | 0.760 |
Why?
| | Enoxaparin | 1 | 2023 | 68 | 0.750 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 338 | 0.720 |
Why?
| | Vascular Surgical Procedures | 2 | 2019 | 342 | 0.710 |
Why?
| | Transplant Donor Site | 1 | 2021 | 3 | 0.710 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 26 | 0.700 |
Why?
| | Humans | 99 | 2026 | 144748 | 0.680 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2016 | 685 | 0.670 |
Why?
| | Pressure Ulcer | 2 | 2011 | 46 | 0.660 |
Why?
| | Diphtheria Toxin | 4 | 2025 | 65 | 0.590 |
Why?
| | Anticoagulants | 2 | 2023 | 733 | 0.580 |
Why?
| | Tissue Transplantation | 3 | 2012 | 9 | 0.570 |
Why?
| | Kidney Transplantation | 5 | 2012 | 710 | 0.560 |
Why?
| | Nipples | 1 | 2018 | 12 | 0.550 |
Why?
| | Female | 60 | 2025 | 78074 | 0.540 |
Why?
| | Swine | 11 | 2024 | 839 | 0.540 |
Why?
| | Models, Animal | 4 | 2024 | 392 | 0.520 |
Why?
| | Tomography, X-Ray Computed | 4 | 2026 | 2798 | 0.510 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2016 | 27 | 0.500 |
Why?
| | Treatment Outcome | 22 | 2025 | 11498 | 0.500 |
Why?
| | Tissue and Organ Harvesting | 2 | 2014 | 75 | 0.480 |
Why?
| | Patient Safety | 1 | 2019 | 343 | 0.460 |
Why?
| | Middle Aged | 31 | 2025 | 35640 | 0.460 |
Why?
| | Internet | 3 | 2025 | 701 | 0.460 |
Why?
| | Bone Marrow Cells | 1 | 2016 | 319 | 0.450 |
Why?
| | Frontal Bone | 2 | 2025 | 21 | 0.450 |
Why?
| | Malpractice | 2 | 2025 | 45 | 0.450 |
Why?
| | Groin | 1 | 2014 | 13 | 0.430 |
Why?
| | Perineum | 1 | 2014 | 38 | 0.430 |
Why?
| | Orbit | 2 | 2025 | 70 | 0.430 |
Why?
| | Cleft Lip | 2 | 2025 | 65 | 0.420 |
Why?
| | Pregnancy, Animal | 1 | 2014 | 52 | 0.420 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 30 | 0.420 |
Why?
| | Bone Transplantation | 3 | 2025 | 90 | 0.420 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1372 | 0.420 |
Why?
| | Patient Satisfaction | 3 | 2024 | 702 | 0.420 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2025 | 98 | 0.420 |
Why?
| | Negative-Pressure Wound Therapy | 2 | 2024 | 30 | 0.420 |
Why?
| | Swine, Miniature | 8 | 2024 | 90 | 0.400 |
Why?
| | Interleukin-2 | 4 | 2024 | 451 | 0.400 |
Why?
| | Length of Stay | 6 | 2025 | 1317 | 0.390 |
Why?
| | Pelvis | 1 | 2014 | 124 | 0.390 |
Why?
| | Adult | 30 | 2025 | 40359 | 0.390 |
Why?
| | Dogs | 5 | 2016 | 431 | 0.380 |
Why?
| | Facial Injuries | 2 | 2009 | 24 | 0.370 |
Why?
| | Face | 2 | 2013 | 174 | 0.370 |
Why?
| | Prosthesis-Related Infections | 2 | 2024 | 98 | 0.350 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 2 | 2023 | 45 | 0.350 |
Why?
| | Communications Media | 1 | 2011 | 4 | 0.350 |
Why?
| | Abdomen | 3 | 2024 | 140 | 0.340 |
Why?
| | United States | 19 | 2025 | 15694 | 0.340 |
Why?
| | Surgical Mesh | 2 | 2025 | 52 | 0.340 |
Why?
| | Bariatric Surgery | 2 | 2024 | 233 | 0.330 |
Why?
| | Medicaid | 2 | 2025 | 462 | 0.330 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 129 | 0.330 |
Why?
| | Attitude of Health Personnel | 2 | 2009 | 1222 | 0.330 |
Why?
| | Animals | 23 | 2025 | 38224 | 0.320 |
Why?
| | Computed Tomography Angiography | 2 | 2022 | 143 | 0.320 |
Why?
| | Obesity, Morbid | 2 | 2024 | 278 | 0.320 |
Why?
| | Coitus | 1 | 2010 | 23 | 0.320 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2010 | 40 | 0.310 |
Why?
| | Ultrasonography, Doppler | 1 | 2010 | 127 | 0.310 |
Why?
| | Osteomyelitis | 1 | 2011 | 143 | 0.300 |
Why?
| | Body Mass Index | 3 | 2024 | 2453 | 0.300 |
Why?
| | Arteries | 2 | 2013 | 262 | 0.300 |
Why?
| | Amputation, Traumatic | 1 | 2009 | 21 | 0.290 |
Why?
| | Traumatology | 1 | 2009 | 36 | 0.290 |
Why?
| | Hand Injuries | 1 | 2009 | 32 | 0.290 |
Why?
| | Follow-Up Studies | 9 | 2024 | 5345 | 0.290 |
Why?
| | Suture Techniques | 2 | 2024 | 128 | 0.280 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 251 | 0.280 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2008 | 21 | 0.270 |
Why?
| | Thigh | 1 | 2008 | 49 | 0.270 |
Why?
| | Vagina | 1 | 2010 | 201 | 0.270 |
Why?
| | Hypertrophy | 2 | 2024 | 134 | 0.260 |
Why?
| | Skin Neoplasms | 3 | 2023 | 870 | 0.260 |
Why?
| | Intraoperative Complications | 2 | 2025 | 156 | 0.260 |
Why?
| | Reoperation | 5 | 2025 | 603 | 0.260 |
Why?
| | Sternum | 2 | 2024 | 29 | 0.260 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 101 | 0.260 |
Why?
| | Sternotomy | 2 | 2024 | 26 | 0.250 |
Why?
| | Back | 1 | 2006 | 11 | 0.250 |
Why?
| | Orthopedics | 1 | 2009 | 158 | 0.250 |
Why?
| | Cannabis | 2 | 2023 | 521 | 0.240 |
Why?
| | Wounds and Injuries | 2 | 2012 | 955 | 0.240 |
Why?
| | Cephalometry | 1 | 2026 | 35 | 0.240 |
Why?
| | Orthognathic Surgical Procedures | 1 | 2025 | 9 | 0.230 |
Why?
| | Nerve Block | 2 | 2025 | 100 | 0.230 |
Why?
| | Head and Neck Neoplasms | 3 | 2025 | 567 | 0.230 |
Why?
| | Internship and Residency | 3 | 2025 | 1256 | 0.230 |
Why?
| | Scalp | 1 | 2025 | 39 | 0.230 |
Why?
| | Liability, Legal | 1 | 2025 | 43 | 0.230 |
Why?
| | Histocompatibility | 3 | 2014 | 21 | 0.230 |
Why?
| | Inflation, Economic | 1 | 2025 | 3 | 0.230 |
Why?
| | Facial Paralysis | 1 | 2025 | 24 | 0.230 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2025 | 66 | 0.220 |
Why?
| | Iatrogenic Disease | 1 | 2025 | 78 | 0.220 |
Why?
| | Muscular Dystrophy, Facioscapulohumeral | 1 | 2025 | 30 | 0.220 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2025 | 26 | 0.220 |
Why?
| | CD47 Antigen | 1 | 2025 | 43 | 0.220 |
Why?
| | Implant Capsular Contracture | 1 | 2024 | 5 | 0.220 |
Why?
| | Transplantation Conditioning | 3 | 2016 | 187 | 0.220 |
Why?
| | Societies, Medical | 1 | 2009 | 878 | 0.220 |
Why?
| | Health Care Reform | 1 | 2025 | 109 | 0.220 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 86 | 0.220 |
Why?
| | Fibula | 1 | 2024 | 40 | 0.210 |
Why?
| | Gender Dysphoria | 1 | 2024 | 19 | 0.210 |
Why?
| | Anastomosis, Surgical | 3 | 2020 | 159 | 0.210 |
Why?
| | Physical Therapy Modalities | 2 | 2024 | 328 | 0.210 |
Why?
| | Telemedicine | 2 | 2025 | 929 | 0.210 |
Why?
| | Cleft Palate | 1 | 2025 | 82 | 0.210 |
Why?
| | Publishing | 1 | 2025 | 111 | 0.200 |
Why?
| | Body Contouring | 1 | 2023 | 9 | 0.200 |
Why?
| | Malocclusion | 1 | 2023 | 24 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2025 | 234 | 0.200 |
Why?
| | Vitamin D Deficiency | 1 | 2025 | 189 | 0.200 |
Why?
| | Insurance | 1 | 2023 | 14 | 0.200 |
Why?
| | Sezary Syndrome | 1 | 2023 | 45 | 0.200 |
Why?
| | Mandibular Fractures | 1 | 2023 | 18 | 0.200 |
Why?
| | Fetus | 2 | 2005 | 807 | 0.200 |
Why?
| | Mycosis Fungoides | 1 | 2023 | 62 | 0.200 |
Why?
| | Skull Fractures | 1 | 2023 | 38 | 0.200 |
Why?
| | Hindlimb | 2 | 2003 | 136 | 0.190 |
Why?
| | Seroma | 1 | 2022 | 3 | 0.190 |
Why?
| | Extremities | 2 | 2002 | 141 | 0.180 |
Why?
| | Weight Loss | 1 | 2008 | 827 | 0.180 |
Why?
| | Risk Factors | 7 | 2024 | 10739 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2209 | 0.180 |
Why?
| | Time Factors | 7 | 2025 | 7074 | 0.180 |
Why?
| | Incidental Findings | 1 | 2022 | 81 | 0.180 |
Why?
| | Clinical Protocols | 1 | 2023 | 283 | 0.180 |
Why?
| | Quality of Life | 4 | 2025 | 3100 | 0.170 |
Why?
| | Educational Measurement | 1 | 2024 | 332 | 0.170 |
Why?
| | Hypotension | 1 | 2022 | 127 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3834 | 0.170 |
Why?
| | Transplantation, Autologous | 3 | 2024 | 288 | 0.170 |
Why?
| | Proteus vulgaris | 1 | 2000 | 1 | 0.170 |
Why?
| | Mediastinitis | 1 | 2000 | 3 | 0.170 |
Why?
| | Proteus Infections | 1 | 2000 | 5 | 0.170 |
Why?
| | Male | 21 | 2025 | 72211 | 0.170 |
Why?
| | Cyclosporine | 3 | 2016 | 266 | 0.170 |
Why?
| | Analgesics, Opioid | 3 | 2025 | 1144 | 0.170 |
Why?
| | Imaging, Three-Dimensional | 3 | 2026 | 574 | 0.160 |
Why?
| | Epidermal Growth Factor | 1 | 2021 | 174 | 0.160 |
Why?
| | Patient Education as Topic | 1 | 2025 | 786 | 0.160 |
Why?
| | Motivation | 1 | 2025 | 621 | 0.160 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2014 | 399 | 0.160 |
Why?
| | Machine Learning | 1 | 2026 | 580 | 0.150 |
Why?
| | Blood Vessel Prosthesis | 1 | 2000 | 139 | 0.150 |
Why?
| | Flow Cytometry | 4 | 2020 | 1193 | 0.150 |
Why?
| | Keloid | 1 | 2019 | 8 | 0.150 |
Why?
| | Patient Discharge | 1 | 2025 | 933 | 0.150 |
Why?
| | Dermis | 1 | 2019 | 33 | 0.150 |
Why?
| | Antigens | 2 | 2016 | 350 | 0.150 |
Why?
| | Aortic Aneurysm, Thoracic | 1 | 2000 | 137 | 0.140 |
Why?
| | Postoperative Period | 2 | 2023 | 360 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 706 | 0.140 |
Why?
| | Mice, SCID | 3 | 2025 | 374 | 0.140 |
Why?
| | Incidence | 2 | 2023 | 2864 | 0.140 |
Why?
| | Tattooing | 1 | 2018 | 11 | 0.140 |
Why?
| | Fluorouracil | 1 | 2019 | 210 | 0.140 |
Why?
| | Indocyanine Green | 2 | 2022 | 42 | 0.130 |
Why?
| | Chimera | 2 | 2011 | 61 | 0.130 |
Why?
| | Data Collection | 2 | 2011 | 658 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1084 | 0.130 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 84 | 0.130 |
Why?
| | Risk Assessment | 3 | 2024 | 3595 | 0.130 |
Why?
| | Graft vs Host Disease | 2 | 2016 | 262 | 0.130 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2016 | 89 | 0.120 |
Why?
| | Hernia, Ventral | 1 | 2016 | 24 | 0.120 |
Why?
| | Bupivacaine | 1 | 2016 | 39 | 0.120 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 121 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6062 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 76 | 0.120 |
Why?
| | Aged | 9 | 2025 | 25564 | 0.110 |
Why?
| | Prospective Studies | 3 | 2021 | 7956 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1167 | 0.110 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 580 | 0.110 |
Why?
| | Leukocytes | 1 | 2016 | 299 | 0.110 |
Why?
| | Whole-Body Irradiation | 2 | 2012 | 78 | 0.110 |
Why?
| | Muscle, Skeletal | 2 | 2006 | 1802 | 0.110 |
Why?
| | Databases, Factual | 3 | 2025 | 1478 | 0.110 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2014 | 51 | 0.110 |
Why?
| | Myeloablative Agonists | 1 | 2014 | 23 | 0.110 |
Why?
| | Cadaver | 2 | 2010 | 306 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 949 | 0.110 |
Why?
| | False Negative Reactions | 1 | 2014 | 62 | 0.110 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1514 | 0.100 |
Why?
| | Patient Selection | 2 | 2008 | 699 | 0.100 |
Why?
| | CD3 Complex | 1 | 2014 | 110 | 0.100 |
Why?
| | Temporal Arteries | 1 | 2014 | 44 | 0.100 |
Why?
| | False Positive Reactions | 1 | 2014 | 123 | 0.100 |
Why?
| | Dissection | 1 | 2014 | 56 | 0.100 |
Why?
| | Histocompatibility Antigens | 1 | 2014 | 108 | 0.100 |
Why?
| | Endrin | 2 | 2023 | 13 | 0.100 |
Why?
| | Allografts | 1 | 2014 | 151 | 0.100 |
Why?
| | Random Allocation | 1 | 2014 | 370 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1916 | 0.100 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 204 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Multidetector Computed Tomography | 1 | 2013 | 40 | 0.100 |
Why?
| | Prostheses and Implants | 1 | 2014 | 145 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2021 | 3403 | 0.090 |
Why?
| | Health Care Costs | 1 | 2016 | 421 | 0.090 |
Why?
| | Receptors, CCR4 | 2 | 2024 | 23 | 0.090 |
Why?
| | Pain Management | 1 | 2016 | 405 | 0.090 |
Why?
| | Recurrence | 2 | 2019 | 1135 | 0.090 |
Why?
| | Monitoring, Physiologic | 1 | 2014 | 290 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2014 | 506 | 0.090 |
Why?
| | Paternalism | 1 | 2011 | 4 | 0.090 |
Why?
| | Beneficence | 1 | 2011 | 20 | 0.090 |
Why?
| | Collagen | 1 | 2014 | 468 | 0.090 |
Why?
| | Marketing of Health Services | 1 | 2011 | 15 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2012 | 195 | 0.090 |
Why?
| | Mice, Inbred NOD | 2 | 2025 | 611 | 0.090 |
Why?
| | Personal Autonomy | 1 | 2011 | 56 | 0.080 |
Why?
| | Intraoperative Care | 1 | 2011 | 63 | 0.080 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 1478 | 0.080 |
Why?
| | Ethics, Medical | 1 | 2011 | 83 | 0.080 |
Why?
| | Mice | 6 | 2025 | 18497 | 0.080 |
Why?
| | Professional Practice | 1 | 2011 | 62 | 0.080 |
Why?
| | Treatment Failure | 1 | 2012 | 362 | 0.080 |
Why?
| | Infant | 4 | 2025 | 10095 | 0.080 |
Why?
| | Child | 6 | 2025 | 22928 | 0.080 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3626 | 0.080 |
Why?
| | Neovascularization, Physiologic | 1 | 2011 | 193 | 0.080 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2010 | 37 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2014 | 4553 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2010 | 93 | 0.080 |
Why?
| | Informed Consent | 1 | 2011 | 196 | 0.080 |
Why?
| | Radiography, Abdominal | 1 | 2010 | 44 | 0.080 |
Why?
| | Logistic Models | 2 | 2016 | 2111 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1993 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1566 | 0.080 |
Why?
| | North America | 1 | 2009 | 312 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2011 | 254 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2021 | 681 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 727 | 0.070 |
Why?
| | Health Care Surveys | 1 | 2009 | 566 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2009 | 334 | 0.060 |
Why?
| | Back Injuries | 1 | 2006 | 6 | 0.060 |
Why?
| | Omentum | 1 | 2006 | 9 | 0.060 |
Why?
| | Wound Healing | 2 | 2023 | 365 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2010 | 238 | 0.060 |
Why?
| | Linear Models | 1 | 2008 | 860 | 0.060 |
Why?
| | Case Management | 1 | 2006 | 66 | 0.060 |
Why?
| | Cytokines | 1 | 2014 | 2102 | 0.060 |
Why?
| | Debridement | 1 | 2006 | 91 | 0.060 |
Why?
| | Photogrammetry | 1 | 2026 | 10 | 0.060 |
Why?
| | Insurance, Liability | 1 | 2025 | 9 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1315 | 0.060 |
Why?
| | Child, Preschool | 3 | 2025 | 11876 | 0.060 |
Why?
| | Current Procedural Terminology | 1 | 2025 | 20 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2012 | 1109 | 0.060 |
Why?
| | Major Histocompatibility Complex | 1 | 2005 | 233 | 0.060 |
Why?
| | Craniotomy | 1 | 2025 | 82 | 0.050 |
Why?
| | Silicone Gels | 1 | 2024 | 4 | 0.050 |
Why?
| | Operative Time | 1 | 2025 | 177 | 0.050 |
Why?
| | Licensure, Medical | 1 | 2024 | 19 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2098 | 0.050 |
Why?
| | Melanoma | 1 | 2012 | 811 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2024 | 84 | 0.050 |
Why?
| | School Admission Criteria | 1 | 2024 | 34 | 0.050 |
Why?
| | Esthetics | 1 | 2024 | 48 | 0.050 |
Why?
| | Pectoralis Muscles | 1 | 2024 | 20 | 0.050 |
Why?
| | Burns | 1 | 2009 | 365 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1063 | 0.050 |
Why?
| | Comprehension | 1 | 2025 | 181 | 0.050 |
Why?
| | Hydrocodone | 1 | 2023 | 19 | 0.050 |
Why?
| | Personnel Selection | 1 | 2024 | 90 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 559 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2025 | 6418 | 0.050 |
Why?
| | Tobacco Use | 1 | 2023 | 66 | 0.050 |
Why?
| | Mandible | 1 | 2023 | 72 | 0.050 |
Why?
| | Adolescent | 4 | 2025 | 22670 | 0.050 |
Why?
| | Chemoprevention | 1 | 2023 | 95 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4276 | 0.050 |
Why?
| | Pain Measurement | 1 | 2025 | 562 | 0.050 |
Why?
| | Electromyography | 1 | 2025 | 414 | 0.050 |
Why?
| | Young Adult | 4 | 2024 | 14021 | 0.050 |
Why?
| | Tissue Donors | 1 | 2005 | 413 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2024 | 241 | 0.050 |
Why?
| | Physicians | 1 | 2011 | 941 | 0.050 |
Why?
| | Umbilicus | 1 | 2022 | 19 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5797 | 0.050 |
Why?
| | Transplantation Immunology | 1 | 2002 | 31 | 0.050 |
Why?
| | Genetic Testing | 1 | 2025 | 475 | 0.050 |
Why?
| | Vitamin D | 1 | 2025 | 401 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2002 | 72 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8103 | 0.040 |
Why?
| | Perfusion | 1 | 2022 | 243 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 468 | 0.040 |
Why?
| | Pregnancy | 1 | 2014 | 7211 | 0.040 |
Why?
| | Cicatrix | 1 | 2022 | 71 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2024 | 580 | 0.040 |
Why?
| | Erlotinib Hydrochloride | 1 | 2021 | 69 | 0.040 |
Why?
| | Povidone-Iodine | 1 | 2000 | 11 | 0.040 |
Why?
| | Insurance, Health | 1 | 2023 | 303 | 0.040 |
Why?
| | Musculoskeletal System | 1 | 2001 | 49 | 0.040 |
Why?
| | Lymphocyte Depletion | 1 | 2001 | 136 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 70 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 91 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2020 | 80 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 426 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2000 | 122 | 0.040 |
Why?
| | Patient Readmission | 1 | 2025 | 716 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 380 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 840 | 0.040 |
Why?
| | Forelimb | 1 | 1999 | 39 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2022 | 617 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 306 | 0.040 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 552 | 0.040 |
Why?
| | Injections, Intralesional | 1 | 2019 | 36 | 0.040 |
Why?
| | Immunity, Cellular | 1 | 2001 | 269 | 0.040 |
Why?
| | Lymphocytes | 1 | 2001 | 400 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2019 | 116 | 0.040 |
Why?
| | Medicare | 1 | 2024 | 812 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 737 | 0.030 |
Why?
| | Tacrolimus | 1 | 1999 | 200 | 0.030 |
Why?
| | Veterans | 1 | 2010 | 1565 | 0.030 |
Why?
| | Skin | 1 | 2003 | 774 | 0.030 |
Why?
| | Margins of Excision | 1 | 2017 | 48 | 0.030 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 54 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1372 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2019 | 342 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 892 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 3076 | 0.030 |
Why?
| | Narcotics | 1 | 2016 | 55 | 0.030 |
Why?
| | Cost Savings | 1 | 2016 | 86 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 441 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2016 | 103 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1091 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 494 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5615 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 311 | 0.030 |
Why?
| | Tissue Expansion Devices | 1 | 2014 | 5 | 0.030 |
Why?
| | Tissue Expansion | 1 | 2014 | 10 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 983 | 0.030 |
Why?
| | Cellulitis | 1 | 2014 | 55 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 689 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2014 | 131 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5895 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 629 | 0.020 |
Why?
| | Leukocyte Transfusion | 1 | 2012 | 4 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2017 | 576 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1801 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 208 | 0.020 |
Why?
| | Fluorescence | 1 | 2011 | 163 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1762 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 2597 | 0.020 |
Why?
| | Burns, Electric | 1 | 2009 | 26 | 0.020 |
Why?
| | Equipment Design | 1 | 2011 | 535 | 0.020 |
Why?
| | Neurofibromatosis 1 | 1 | 2009 | 55 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1685 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 1064 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4704 | 0.020 |
Why?
| | Smoking | 1 | 2014 | 1583 | 0.020 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 251 | 0.010 |
Why?
| | Recovery of Function | 1 | 2009 | 704 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1091 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 250 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2001 | 156 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4185 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2004 | 2042 | 0.010 |
Why?
|
|
Mathes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|